Straumann I

Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.

17 papers · ORCID

ArticlePsilocybin

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Arikci D, Borgulya J, Straumann I +8

Europe PMC2026
ArticleDMT

Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants.

Erne L, Mueller L, Straumann I +7

Europe PMC2026
ArticlePsilocybin

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.

Stocker K, Hartmann M, Schmid Y +10

Europe PMC2026
ArticleMDMA

Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants.

Straumann I, Vizeli P, Avedisian I +7

Europe PMC2026
ArticleLSD

Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.

Mueller L, Santos de Jesus J, Schmid Y +9

Europe PMC2025
ArticlePsilocybin

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Ley L, Liechti ME, Becker AM +6

Europe PMC2025
ArticleLSD

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial.

Becker AM, Humbert-Droz M, Mueller L +10

Europe PMC2025
ArticleMDMA

Oxytocin and the Role of Fluid Restriction in MDMA-Induced Hyponatremia: A Secondary Analysis of 4 Randomized Clinical Trials.

Atila C, Straumann I, Vizeli P +5

Europe PMC2024
ArticleMescaline

Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.

Klaiber A, Schmid Y, Becker AM +6

Europe PMC2024
ArticleLSD

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.

Vizeli P, Studerus E, Holze F +8

Europe PMC2024
ArticleMDMA

Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind cross-over trial in healthy participants.

Straumann I, Avedisian I, Klaiber A +5

Europe PMC2024
ArticlePsilocybin

Safety pharmacology of acute psilocybin administration in healthy participants.

Straumann I, Holze F, Becker AM +3

Europe PMC2024
ArticleMDMA

Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.

Straumann I, Ley L, Holze F +7

Europe PMC2023
ArticlePsilocybin

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.

Ley L, Holze F, Arikci D +11

Europe PMC2023
ArticleDMT

Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants.

Vogt SB, Ley L, Erne L +12

Europe PMC2023
ArticlePsilocybin

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.

Holze F, Ley L, Müller F +10

Europe PMC2022
ArticleLSD

Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.

Vizeli P, Straumann I, Holze F +3

Europe PMC2021